niacinamide has been researched along with sar405838 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Archibald, HL; Debussche, L; Engelman, JA; Gomez-Caraballo, M; Hata, AN; Ji, F; Jung, J; Lee, JS; Light, M; Rowley, S; Sadreyev, RI; Siddiqui, FM; Sidhu, S; Watters, J | 1 |
de Jonge, M; de Weger, VA; Demers, B; Deutsch, E; Goodstal, S; Hsu, K; Langenberg, MHG; Lolkema, M; Macé, S; Schellens, JHM; Thomas, K; Tuffal, G; Varga, A | 1 |
1 trial(s) available for niacinamide and sar405838
Article | Year |
---|---|
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; MAP Kinase Kinase Kinases; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins p21(ras); Spiro Compounds; Thrombocytopenia; Tumor Suppressor Protein p53 | 2019 |
1 other study(ies) available for niacinamide and sar405838
Article | Year |
---|---|
Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Topics: A549 Cells; Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockdown Techniques; HCT116 Cells; Humans; Indoles; Lung Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Mutation; Niacinamide; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins p21(ras); RNA Interference; RNA, Small Interfering; Spiro Compounds; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |